Moderna (MRNA) excited analysts, though not as much investors, with its announcement this week that it planned to file for approval of its mRNA vaccine designed to protect older adults against respiratory syncytial virus (RSV) after it demonstrated success in a Phase III trial.
After…
Source: www.genengnews.com – Read more
Week in review: NIST updates DNS security guidance, compromised LiteLLM PyPI packages
Here’s an overview of some of last week’s most interesting news, articles, interviews and videos: NIST updates its DNS security guidance for the first time
